Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Hospira Unveils New Quality Laboratory

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
New quality laboratory and technological advances improve manufacturing flow and enhance ability to supply customers with life-impacting drugs.

Hospira, Inc. has unveiled a new quality and analytical testing laboratory at its Rocky Mount, N.C., plant in a ribbon-cutting ceremony attended by North Carolina Governor Pat McCrory and other local and state government leaders.

The ceremony highlighted the importance of the quality laboratory, and all of the capital improvements at the plant, to Hospira, the local community and patients around the globe.

"Rocky Mount's new laboratory, coupled with our investments throughout the plant, will help ensure that we continue to supply high-quality, more affordable medicines to customers and patients who need them," said Marty Nealey, vice president, Rocky Mount Operations, Hospira.

Nealey continued, "Through advanced technology and additional space, we've been able to gradually increase our production levels and ensure more consistent release of products, ultimately supporting our ability to provide a more sustainable supply of many life-impacting drugs. I'm very proud of all of the team members here at Rocky Mount and very thankful for the support of this community and our state in furthering our commitment to advancing wellness."

Part of Hospira's more than $200 million investment at Rocky Mount, which includes significant capital investments, this new, quality laboratory will be home to 200 employees, responsible for evaluating and testing more than 450 different products.

The laboratory features the latest technology and advancements in quality and analytical testing and inspection.

The construction of the quality laboratory was made possible, in part, by local and state incentives, including a grant from the One North Carolina Fund, which provides financial assistance, through local governments, to attract business projects that will stimulate economic activity and create new jobs in the state. Since the grant was awarded, Hospira has added nearly 200 jobs to the Rocky Mount plant overall.

"Creating jobs in North Carolina is one of my top priorities and I would like to thank Hospira for its investment in Rocky Mount and North Carolina," said Governor Pat McCrory. "We have a very strong and talented workforce that will provide Hospira with skilled workers that they are looking for. We look forward to a great relationship and watching the company grow here in North Carolina."

The opening of the quality lab and other improvements at the Rocky Mount plant are part of a broad effort by Hospira to ensure consistent access to its more affordable, high-quality drugs.

"For nearly 80 years, Hospira has been an integral part of the healthcare system, serving hundreds of millions of patients with affordable drugs and delivery systems worldwide," said F. Michael Ball, chief executive officer, Hospira, at today's ceremony.

Ball continued, "We are investing more than $1 billion globally to not only serve the patients and hospitals that depend on us with high-quality products in sustainable supply today, but also to make sure that our central role in this system remains vibrant in the future."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer Completes Acquisition of Hospira
Expected to be immediately accretive to adjusted diluted EPS1 upon closing.
Friday, September 11, 2015
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos